Studi Farmakovigilans Pengobatan MDR-TB pada Pasien Rawat Jalan di RSUD Embung Fatimah Kota Batam Tahun 2020
Study of MDR-TB Treatment Pharmacovigilans in Outpatients at Embung Fatimah Hospital Batam City in 2020
DOI:
https://doi.org/10.33084/jsm.v8i2.3909Keywords:
Pharmacovigilance, MDR-TB, Side Effects, Nausea- VomitingAbstract
Pharmacovigilance is a science related to collecting, detecting, monitoring, assessing, and preventing side effects of pharmaceutical products. The design of this research is retrospectively descriptive. To understand the characteristics of MDR-TB patients and the side effects of the drug that MDR-TB patients feel. The research was conducted between January 2020 – June 2020. The research was conducted at Embung Fatimah Hospital. The number of confirmed patients with MDR TB was 24 patients, 9 male (37.5%) and 15 women (62.5%); the average MDR-TB patient aged 26-45 years (54.20%), Batu Aji (45.83%) be the place most exposed to MDR-TB with a social history of smoking, drugs, and alcohol. The results showed patients who experienced 41.7% anorexia side effects, 100% nausea, 100% vomiting, reduced appetite by 37.5%, 79.2% pain at the injection site, 79.2% joint pain, 58.3% reduced hearing and 25% vertigo. In conclusion, most side effects are nausea and vomiting.
Downloads
Download data is not yet available.
References
1. WHO. (2012). A practical handbook on the pharmacovigilance of medicines used in the treatment of tuberculosis.
2. Goedecke, T., Morales, D. R., Pacurariu, A., & Kurz, X. (2018). Measuring the impact of medicines regulatory interventions – Systematic review and methodological considerations. British Journal of Clinical Pharmacology.
3. Devi, M., & Sinuraya, R. K. (2018). Pharmacovigilance Dalam Aspek Penanganan Reaksi Obat Yang Tidak Diinginkan: Sebuah Artikel Review. Farmaka, 16(Vol 16, No 1).
4. Peraturan Menteri Kesehatan Republik Indonesia No 67 Tahun 2016 tentang Penanggulangan Tuberkulosis. 2016.
5. Kementerian Kesehatan Republik Indonesia (2018). Pusat Data dan Informasi (Infodatin). Jakarta.
6. Kementerian Kesehatan Republik Indonesia. (2011). Pedoman Nasional Pengendalian Tuberkulosis-Keputusan Menteri Kesehatan Republik Indonesia Nomor 364. Jurnal ICT, (Pengendalian Tuberkulosis), 110.
7. Nugi, N. (2020). Analysis of Individual Risk Factors for Tuberculosis Multidrug-Resistant (MDR TB) in South Sumatra Province. 2020;6(1)
8. Rohan, H., Kale, A. S., Dakhale, G. N., & Gaikwad, N. (2014). A prospective, observational study of adverse reactions to drug regimen for multi-drug resistant pulmonary tuberculosis in central India. Mediterranean Journal of Hematology and Infectious Diseases, 6(1).
9. Reviono, Kusnanto, P., Eko, V., Pakiding, H., & Nurwidiasih, D. (2014). Multidrug Resistant Tuberculosis (MDR-TB): Tinjauan Epidemiologi dan Faktor Risiko Efek Samping Obat Anti Tuberkulosis. Majalah Kedokteran Bandung, 46(4), 189–196.
10. Mirza S. B., Kale, M. R., & Lamb, A. (2018). A prospective observational pharmacovigilance study of adverse drug reaction monitoring in patients of MDR-TB at tertiary care hospital. International Journal of Basic & Clinical Pharmacology, 7(7), 1291.
11. Nadia, A., Misbahul, H., Marhamah. (2017). Gambaran Penderita Tuberculosis Multi Drug Resistan(TB MDR) Di RSUD Dr. H. Abdul Moeloek Provinsi Lampung Januari-Desember 2015. (Vol 6, No 2).
12. Vivin, A., Indra, S., Dina, F. (2015). Profil Pasien Tuberculosis Multidrug Resistance (MDR-TB) di Poliklinik MDR-TB RSUD Arifin Achman Provinsi Riau Periode April 2013 – Juni 2014.
13. Eva, S, D., Fenny, H., Chairul., N. (2019). Analisis Deskriptif Efek Samping Pengguanaan Obat Anti Tuberculosis Pada Pasien TBC di RSUD Dr. Pringadi Medan.
14. Chynthia, D. A., Magdalena, W. (2018). Faktor-Faktor yang Mempengaruhi Terjadinya Multi Drug Resistance Tuberkulosis (MDR-TB). Jurnal Biomedika dan Kesehatan. Vol.1, 65-74.
15. Nur, A., Sukartini, T., Harmayetty. (2019). Karakteristik Pasien Multidrug Resitant Tuberculosis di RSUD Makassar. Jurnal Penelitian Kesehatan Suara Forikes. (Vol 10, No 4). 2502-7778.
16. Zida, M. A., Nur, M. R. (2019). Karakteristik Penderita Tuberculosis Multidrug Resistant (TB MDR) di Sulawesi Tenggara Tahun 2014-2017. (Vol 6, No 2). 2443-021
17. Mahalul, A., Arulita, I, F., Fitri, I,. Indah, S. (2020). Prevalensi dan Determinan Kejadian Depresi pada Pasien MultiDrug Resistance Tuberculosis: Studi di RSUP Dr. Kariadi Semarang
18. Emmi, B., Munawir, A., Nurbiah. (2018). Faktor Risiko Pengobatan Pasien Multidrug Resistance Tuberculosis (MDR-TB) di RSUD Labung Baji Kota Makassar Tahun 2017. Jurnal Nasional Ilmu Kesehatan. Vol. 1 18(6), 2621- 6507.
19. Umi, F., Tutik, K. (2017). Characteristics and the Side Effects of New MDR-TB Treatment in the Dr. Soetomo Hospital during 2016.
20. Arif, I Della., Nitish, K., Anil, S., Kiran., P. (2020). Adverse drug reactions and treatment outcome analysis of DOTS-plus therapy of MDR-TB patients at district tuberculosis centre: A four year retrospective study. 114.125.13.156.
21. Yohanna, K. A., Petros., Sven, G. H. (2015). Adverse Eventsina Nation Wide Cohort of Patients with Multidrug Resistant Tuberculosis in Nigeria.
22. William, W., Dyah, I., Ahmad, D. W. (2018). Hubungan pemberian Kanamisin dengan kejadian ototoksik pada penderita tuberkulosis multi drug resistance. (Vol 48, No 2).
23. Musdalipah., Etty, N., Karmilah., Fakhrurazi, M. (2018). Efek Samping Obat Anti Tuberkulosis (OAT) dan Penanganannya Pada Pasien Tuberkulosis (TB) di Puskesmas Perumnas Kota Kendari. 4(1), 67-73.
2. Goedecke, T., Morales, D. R., Pacurariu, A., & Kurz, X. (2018). Measuring the impact of medicines regulatory interventions – Systematic review and methodological considerations. British Journal of Clinical Pharmacology.
3. Devi, M., & Sinuraya, R. K. (2018). Pharmacovigilance Dalam Aspek Penanganan Reaksi Obat Yang Tidak Diinginkan: Sebuah Artikel Review. Farmaka, 16(Vol 16, No 1).
4. Peraturan Menteri Kesehatan Republik Indonesia No 67 Tahun 2016 tentang Penanggulangan Tuberkulosis. 2016.
5. Kementerian Kesehatan Republik Indonesia (2018). Pusat Data dan Informasi (Infodatin). Jakarta.
6. Kementerian Kesehatan Republik Indonesia. (2011). Pedoman Nasional Pengendalian Tuberkulosis-Keputusan Menteri Kesehatan Republik Indonesia Nomor 364. Jurnal ICT, (Pengendalian Tuberkulosis), 110.
7. Nugi, N. (2020). Analysis of Individual Risk Factors for Tuberculosis Multidrug-Resistant (MDR TB) in South Sumatra Province. 2020;6(1)
8. Rohan, H., Kale, A. S., Dakhale, G. N., & Gaikwad, N. (2014). A prospective, observational study of adverse reactions to drug regimen for multi-drug resistant pulmonary tuberculosis in central India. Mediterranean Journal of Hematology and Infectious Diseases, 6(1).
9. Reviono, Kusnanto, P., Eko, V., Pakiding, H., & Nurwidiasih, D. (2014). Multidrug Resistant Tuberculosis (MDR-TB): Tinjauan Epidemiologi dan Faktor Risiko Efek Samping Obat Anti Tuberkulosis. Majalah Kedokteran Bandung, 46(4), 189–196.
10. Mirza S. B., Kale, M. R., & Lamb, A. (2018). A prospective observational pharmacovigilance study of adverse drug reaction monitoring in patients of MDR-TB at tertiary care hospital. International Journal of Basic & Clinical Pharmacology, 7(7), 1291.
11. Nadia, A., Misbahul, H., Marhamah. (2017). Gambaran Penderita Tuberculosis Multi Drug Resistan(TB MDR) Di RSUD Dr. H. Abdul Moeloek Provinsi Lampung Januari-Desember 2015. (Vol 6, No 2).
12. Vivin, A., Indra, S., Dina, F. (2015). Profil Pasien Tuberculosis Multidrug Resistance (MDR-TB) di Poliklinik MDR-TB RSUD Arifin Achman Provinsi Riau Periode April 2013 – Juni 2014.
13. Eva, S, D., Fenny, H., Chairul., N. (2019). Analisis Deskriptif Efek Samping Pengguanaan Obat Anti Tuberculosis Pada Pasien TBC di RSUD Dr. Pringadi Medan.
14. Chynthia, D. A., Magdalena, W. (2018). Faktor-Faktor yang Mempengaruhi Terjadinya Multi Drug Resistance Tuberkulosis (MDR-TB). Jurnal Biomedika dan Kesehatan. Vol.1, 65-74.
15. Nur, A., Sukartini, T., Harmayetty. (2019). Karakteristik Pasien Multidrug Resitant Tuberculosis di RSUD Makassar. Jurnal Penelitian Kesehatan Suara Forikes. (Vol 10, No 4). 2502-7778.
16. Zida, M. A., Nur, M. R. (2019). Karakteristik Penderita Tuberculosis Multidrug Resistant (TB MDR) di Sulawesi Tenggara Tahun 2014-2017. (Vol 6, No 2). 2443-021
17. Mahalul, A., Arulita, I, F., Fitri, I,. Indah, S. (2020). Prevalensi dan Determinan Kejadian Depresi pada Pasien MultiDrug Resistance Tuberculosis: Studi di RSUP Dr. Kariadi Semarang
18. Emmi, B., Munawir, A., Nurbiah. (2018). Faktor Risiko Pengobatan Pasien Multidrug Resistance Tuberculosis (MDR-TB) di RSUD Labung Baji Kota Makassar Tahun 2017. Jurnal Nasional Ilmu Kesehatan. Vol. 1 18(6), 2621- 6507.
19. Umi, F., Tutik, K. (2017). Characteristics and the Side Effects of New MDR-TB Treatment in the Dr. Soetomo Hospital during 2016.
20. Arif, I Della., Nitish, K., Anil, S., Kiran., P. (2020). Adverse drug reactions and treatment outcome analysis of DOTS-plus therapy of MDR-TB patients at district tuberculosis centre: A four year retrospective study. 114.125.13.156.
21. Yohanna, K. A., Petros., Sven, G. H. (2015). Adverse Eventsina Nation Wide Cohort of Patients with Multidrug Resistant Tuberculosis in Nigeria.
22. William, W., Dyah, I., Ahmad, D. W. (2018). Hubungan pemberian Kanamisin dengan kejadian ototoksik pada penderita tuberkulosis multi drug resistance. (Vol 48, No 2).
23. Musdalipah., Etty, N., Karmilah., Fakhrurazi, M. (2018). Efek Samping Obat Anti Tuberkulosis (OAT) dan Penanganannya Pada Pasien Tuberkulosis (TB) di Puskesmas Perumnas Kota Kendari. 4(1), 67-73.
Downloads
Published
2022-08-31
How to Cite
Setianingsih, S. A., Mayefis, D., & Arifin, H. (2022). Studi Farmakovigilans Pengobatan MDR-TB pada Pasien Rawat Jalan di RSUD Embung Fatimah Kota Batam Tahun 2020: Study of MDR-TB Treatment Pharmacovigilans in Outpatients at Embung Fatimah Hospital Batam City in 2020. Jurnal Surya Medika (JSM), 8(2), 263–269. https://doi.org/10.33084/jsm.v8i2.3909
Issue
Section
Articles
License
All rights reserved. This publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording.
